US5632984A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treatment of macular degeneration
Assignee: Allergan Inc
•
Filing: 1994-09-28
•
Granted: 1997-05-27
•
Expires: 2014-09-28
Abstract
Abstract Intraocular administration of drugs such as α-2a interferon is employed in the treatment of age-related macular degeneration. Intraocular administration obviates the side effects associated with systemic administration, concentrates the drug at the site of the disease, and, where microcapsules are employed, provides continuous, long-lasting treatment.
Inventors
- 👤 Vernon G. Wong
- 👤 King Y. Lee
- 👤 Jerry B. Gin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 15:34
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21; A61K38/212; A61K9/00; A61K9/0012; A61K9/0048; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1641; A61K9/1647
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
61 words
A method of treatment of macular degeneration associated with subretinal neovascularization in a mammalian host, said method comprising the steps of: administering intraocularly interferon to said host in an amount sufficient to elicit a decrease in hemorrhage or leakage associated with said subretinal neovascularization wherein said administering is by at least 3 injections at intervals from about three to 42 days.
Claim 2
Independent Claim
61 words
A method of treatment of macular degeneration associated with subretinal neovascularization in a mammalian host, said method comprising the steps of: administering intraocularly interferon to said host in an amount sufficient to elicit a decrease in hemorrhage or leakage associated with said subretinal neovascularization wherein said administering is by at least 3 injections at intervals from about three to 42 days.
Claim 3
Dependent Claim
12 words
The method according to claim 1, wherein said interferon is α-2a interferon.
Claim 4
Dependent Claim
18 words
The method according to claim 2, wherein said amount is from at least about 10,000 to 640,000 units.
Claim 5
Dependent Claim
21 words
The method according to claim 1, wherein said interferon is encapsulated in a biodegradable microcapsule for slow release of said interferon.
Claim 6
Independent Claim
72 words
A method of treatment of macular degeneration associated with subretinal neovascularization in a human host, said method comprising the steps of: injecting intraocularly at least three injections at intervals of from about three to forty-two days of α-2a interferon to said human host in an amount ranging from at least about 10,000 to 100,000 units, said amount being sufficient to elicit a decrease in hemorrhage or leakage associated with said subretinal neovascularization.
Claim 7
Independent Claim
72 words
A method of treatment of macular degeneration associated with subretinal neovascularization in a human host, said method comprising the steps of: injecting intraocularly at least three injections at intervals of from about three to forty-two days of α-2a interferon to said human host in an amount ranging from at least about 10,000 to 100,000 units, said amount being sufficient to elicit a decrease in hemorrhage or leakage associated with said subretinal neovascularization.
Claim 8
Independent Claim
66 words
A method of treatment of macular degeneration associated with subretinal neovascularization in a human host, said method comprising the steps of: administering intraocularly interferon contained within biodegradable microcapsules to said host in an amount sufficient to maintain an intraocular concentration over a period of from about two weeks to 14 months so as to elicit a decrease in hemorrhage or leakage associated with said subretinal neovascularization.
Claim 9
Independent Claim
66 words
A method of treatment of macular degeneration associated with subretinal neovascularization in a human host, said method comprising the steps of: administering intraocularly interferon contained within biodegradable microcapsules to said host in an amount sufficient to maintain an intraocular concentration over a period of from about two weeks to 14 months so as to elicit a decrease in hemorrhage or leakage associated with said subretinal neovascularization.
Claim 10
Dependent Claim
12 words
The method according to claim 6, wherein said interferon is α-2a interferon.
Claim 11
Dependent Claim
19 words
The method according to claim 7, wherein said intraocular concentration is from at least about 10,000 to 100,000 units.
Claim 12
Dependent Claim
18 words
The method according to claim 6, wherein said biodegradable microcapsules comprise a biocompatible polyester of a hydroxycarboxylic acid.
References Cited (Backward Citations)
US4853224A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-05-26 | 2000-11-25 | 2001-05-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-05-26 | 2004-11-25 | 2005-05-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-05-26 | 2008-11-25 | 2009-05-27 | $7700.00 | Window Closed / Lapsed |